Single-center, phase i, open label, single dose study to evaluate the pharmacokinetics and safety of wck 2349 in patients with hepatic impairment

2016 ◽  
Author(s):  
Richard Preston
Keyword(s):  
Single Dose ◽  
Phase I ◽  
Hepatic Impairment ◽  
Single Center ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study

2018 ◽  
Vol 35 (8) ◽  
pp. 1239-1250 ◽  
Author(s):  
Manabu Kato ◽  
Hitoshi Ishizuka ◽  
Takashi Taguchi ◽  
Kazuhito Shiosakai ◽  
Emi Kamiyama ◽  
...  
Keyword(s):  
Single Dose ◽  
Renal Impairment ◽  
Single Center ◽  
Antidiabetic Drug ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study ◽  
Japanese Subjects

Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study

2011 ◽  
Vol 33 (11) ◽  
pp. 1798-1808 ◽  
Author(s):  
Sreeneeranj Kasichayanula ◽  
Xiaoni Liu ◽  
Weijiang Zhang ◽  
Marc Pfister ◽  
Frank P. LaCreta ◽  
...  
Keyword(s):  
Single Dose ◽  
Safety Profile ◽  
Hepatic Impairment ◽  
Open Label ◽  
Single Dose Study ◽  
Parallel Group ◽  
Dose Study

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

2020 ◽  
Vol 61 (6) ◽  
pp. 1355-1363
Author(s):  
Ying C. Ou ◽  
Richard A. Preston ◽  
Thomas C. Marbury ◽  
Zhiyu Tang ◽  
William Novotny ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

scholarly journals A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

2015 ◽  
Vol 56 (3) ◽  
pp. 316-323 ◽  
Author(s):  
Denes Csonka ◽  
Katharine Hazell ◽  
Edward Waldron ◽  
Sebastien Lorenzo ◽  
Vincent Duval ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men

2014 ◽  
Vol 43 (2) ◽  
pp. 289-297 ◽  
Author(s):  
Ellen Scheers ◽  
Laurent Leclercq ◽  
Jan de Jong ◽  
Nini Bode ◽  
Marc Bockx ◽  
...  
Keyword(s):  
Single Dose ◽  
Phase I ◽  
Open Label ◽  
Single Dose Study ◽  
Healthy Men ◽  
Open Label Phase ◽  
Dose Study

An open-label, single-dose study to assess the effect of hepatic impairment on the pharmacokinetics of mirogabalin

2018 ◽  
Vol 19 (3) ◽  
pp. S74
Author(s):  
K. Duchin ◽  
G. Senaldi ◽  
V. Warren ◽  
J. Lee ◽  
T. Marbury ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

scholarly journals Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin

2018 ◽  
Vol 38 (11) ◽  
pp. 1001-1009 ◽  
Author(s):  
Kenneth Duchin ◽  
Giorgio Senaldi ◽  
Vance Warren ◽  
Thomas Marbury ◽  
Kenneth Lasseter ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Moderate Hepatic Impairment ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

2011 ◽  
Vol 69 (1) ◽  
pp. 221-227 ◽  
Author(s):  
Richat Abbas ◽  
Bruce A. Hug ◽  
Cathie Leister ◽  
Myriam El Gaaloul ◽  
Stephan Chalon ◽  
...  
Keyword(s):  
Single Dose ◽  
Phase I ◽  
Healthy Adult ◽  
Single Dose Study ◽  
Dose Study
Sign in / Sign up

Export Citation Format

Share Document